Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump

Biogen Inc. (NASDAQ:BIIB) connected Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the statement of $1.59.

The Alzheimer's cause shaper reported revenues of $2.28 billion, beating the statement of $2.20 billion, down 7% connected a reported and changeless currency basis.

Biogen connected Friday said fiscal 2025 gross from maturation products accrued 19% year-over-year and offset the year-over-year gross diminution from aggregate sclerosis products, excluding Vumerity.

Don't Miss:

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In astatine $0.85/Share

• Deloitte's #1 Fastest-Growing Software Company Lets Users Earn Money Just by Scrolling — Accredited Investors Can Still Get In astatine $0.50/Share.

Leqembi (Alzheimer's drug) collaboration gross was $47 million, with in-market income of astir $134 million, up 54%, booked by Eisai. U.S. in-market income of astir $78 million, representing continued growth.

Multiple sclerosis gross of $917 cardinal decreased by 14% (down 15% connected changeless currency). Sales of the aggregate sclerosis cause Tysabri were down to $397.5 million from $415.4 million.

Rare illness revenue decreased 4% twelvemonth implicit twelvemonth (-4% connected changeless currency) to $514.6 million. Spinraza's gross decreased to $356.2 cardinal from $421.4 cardinal a twelvemonth ago.

Spinraza's 4th fourth gross declined 15% year-over-year, impacted by the timing of shipments extracurricular the U.S., with afloat twelvemonth gross down 2% year-over-year.

Trending: Blue-chip creation has historically outpaced the S&P 500 since 1995, and fractional investing is present opening this organization plus people to mundane investors.

Revenues from Skyclarys (Friedreich's ataxia drug), acquired via the Reata acquisition, reached $133.4 cardinal during the quarter, up from $102.2 cardinal a twelvemonth ago.

Skyclarys grew planetary patients connected therapy by astir 30% successful 2025; the 4th fourth U.S. gross of astir $89 cardinal was driven by request growth, with ex-U.S. gross of astir $44 cardinal reflecting continued request growth, besides impacted by a one-time reimbursement true-up.

Zurzuvae's (postpartum slump drug) 4th fourth gross of astir $66 cardinal showed beardown continued request growth. Vumerity grew 3% year-over-year successful the 4th fourth to $181.1 million.

"Our 2025 show reflected continued absorption connected beardown execution and fiscal discipline, driven by our gross of astir $1 cardinal from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise," commented Christopher Viehbacher, President and CEO.